Navigation Links
Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
Date:3/28/2008

o fast-scan cyclic voltammetry in anesthetized rats. A stimulation train was delivered to the ventral tegmental area every five minutes and the resultant dopamine and rate of reuptake were measured. Peak concentrations of dopamine and the rate of dopamine reuptake were monitored in response to intraperitoneal injections of MSI-1436, saline or nomafensine (a known inhibitor of DAT). Post-hoc analyses indicated that the peak dopamine concentration and the rate of dopamine reuptake (tau) significantly increased from baseline only after injection with nomifensine and that neither MSI-1436 nor the saline control had an effect on these measurements.

"These studies serve to further confirm the selectivity of MSI-1436 as an inhibitor of PTP-1B and addresses one of the critical issues involved in the development of anti-obesity drugs," states Jack Armstrong, President and Chief Executive Officer of Genaera. "The low addictive potential of MSI-1436 further differentiates it from many other drug candidates in development. While MSI- 1436 is being developed to treat both type 2 diabetes and obesity, we believe it is essential to demonstrate that the side effects seen in other weight-loss only drugs are not observed with MSI-1436. We continue to differentiate MSI- 1436 from other drugs for anti-obesity and anti-diabetes indications through our preclinical studies and look forward to reporting additional supportive clinical data later this year."

The researchers included Dr. Roitman and Seth A. Wescott from the University of Illinois at Chicago, as well as Michael P. McLane, Ph.D. and Henry R. Wolfe, Ph.D. from Genaera.

About Genaera

Genaera Corporation is focused on advancing the science and treatment of metabolic diseases. The Company has significant market opportunities with a first-in-class molecule, trodusquemine (MSI-1436), that has the potential to redefine the treatment paradigm for obesity and type 2 diabetes and is presently in a Phase 1 tria
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
8. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... July 10, 2014 Yesterday, former Congressman ... medical device manufacturing facility. Rep. Kennedy and ... monitors facilitate cutting-edge research in neurological disease and ... mental health advocate, Garen Staglin , created ... fostering fundamental changes that will radically accelerate the ...
(Date:7/10/2014)... July 10, 2014   Ventana Medical Systems, Inc. ... it has entered into an agreement with Merck KGaA, ... EMD Serono in the United States ... with Merck KGaA,s biopharmaceutical division on the development and ... target using Ventana,s proprietary diagnostic assays. In alignment with ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... 2010 VIVUS, Inc. (Nasdaq: VVUS ... of novel therapeutic products, today reported its financial results for ... Third Quarter HighlightsOn September 21, 2010, ... which showed significant and sustained weight loss of greater than ...
... Health, Inc. (Nasdaq: GHDX ) today reported financial results ... Total revenue increased to $46.3 million in the third quarter ... 2009.  Product revenue was $45.8 million in the third quarter of ... the third quarter of 2009. Net income was ...
Cached Medicine Technology:VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 2VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 3VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 4VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 5VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 2Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 3Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 4Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 5Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 6Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 7Genomic Health Announces Third Quarter 2010 Financial Results and Business Progress 8
(Date:7/13/2014)... (PRWEB) July 13, 2014 MarketsandMarkets ... Market [3D Modeling; 3D Scanning; 3D rendering; Layout ... and Analysis (2013 - 2018)”, which analyzes and ... in North America, Western Europe, Eastern Europe, Middle ... report also draws the competitive landscape of the ...
(Date:7/13/2014)... 2014 The Pearland, Texas location of The ... from four months to 12 years of age that offers ... birthday parties and Summer Camps, is now under new ownership. ... Pearland after spending over six years at The Little ... Director. , Berry has over ten years of experience ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... is popular among worldwide women. Its lace wedding gowns ... company has announced its new selection of elegant ... outfits are available at discounted prices (from 25 to ... now offering similar discounts for many other wonderful items. ... designs for sale, including flower girl dresses, wedding dresses, ...
(Date:7/13/2014)... July 13, 2014 A decreased ability to ... impairment and Alzheimer,s disease, while examinations of the ... protein associated with Alzheimer,s, in the brain, according ... today at the Alzheimer,s Association International Conference 2014 ... the studies, the decreased ability to identify odors ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:The Little Gym of Pearland, TX Now Under New Ownership and Management 2Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... 2009: After five years of receiving infliximab (IFX) anti-TNF ... substantial clinical benefit (ASAS40, ASsessment in AS, 40-response) and ... 78.4% of AS patients had no arthritis and 84.9% ... and bone). Over this period, patients continued to show ...
... The board of directors of Abbott today declared a quarterly common dividend ... 342nd consecutive quarterly dividend to be paid by Abbott since 1924. ... at the close of business on July 15, 2009. , , ... an 11 percent increase earlier this year - and was again named ...
... , CHICAGO, June 12 ... driven by the eastern federal states.,This is in large ... potential despite the economic crisis. American investor interest in,Germany ... and Nordex AG shared their success stories at the ...
... OWINGS MILLS, Md., June 12 Medifast, Inc. (NYSE: ... the build out of new corporate-owned Medifast Weight Control Centers. ... more conservative in the build out, and analyze the success ... strong success, the Company will be expanding its investment in ...
... , Travelers Turn to InsureMyTrip.com for Coverage Protection and ... Stating ,the scientific criteria for an influenza pandemic have ... declared the A(H1N1) virus, commonly referred to as Swine ... http://www.newscom.com/cgi-bin/prnh/20070529/NETU076LOGO ) , , "Particularly ...
... of Medicine of the University of Southern California (USC) ... blood cells to breakan occurrence that marks the first ... study provides researchers with the clearest insight yet into ... in the chromosome, says principal investigator Michael R. Lieber, ...
Cached Medicine News:Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 2Health News:IFX anti-TNF therapy associated with clinical benefit over 5 years in patients with active AS 3Health News:American Investors Highlight Successes in Eastern Germany 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 2Health News:Medifast, Inc. to Expand Investment in Corporate Medifast Weight Control Centers 3Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3Health News:USC researchers identify DNA mutation that occurs at beginning point of T-cell lymphoma 2
... The Bledsoe Lever Lock Knee ... quick extension lock of the arthroscopic ... to allow motion for rehabilitation or ... quickly locked "rigidly" in full extension ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... The knee is the ... joint. Repetitive or inappropriate stresses ... often lead to excessive strain. ... the knee joint and activates ...
... knee brace provides maximum support ... of sports and activities. Geared ... pads to support medial and ... and hyperextension stop. 3/16" thick, ...
Medicine Products: